The FOXP1 gene is over-expressed in some B-cell lymphomas. Patients with high FOXP1 levels tend to resist therapy and are given a poor prognosis. We discovered a suite of related proteins that are activated by FOXP1 in lymphoma, several of which are currently being targeted in clinical trials. This project will determine how FOXP1 activates these proteins and whether their inhibition will benefit B-cell lymphoma patients.
|Effective start/end date||8/4/15 → 6/30/20|
- NIH National Cancer Institute (NCI)